FDA to Shift Covid-19 Vaccine Strategy, No Longer Recommend Boosters for Low-Risk Populations

The U.S. Food and Drug Administration (FDA) announced a significant shift in its Covid-19 vaccination strategy, outlining a new regulatory framework that separates high-risk individuals from the broader healthy population in future booster recommendations. This policy change comes in response to consistently low uptake of Covid-19 boosters and growing public skepticism toward blanket vaccination mandates.

For the past five years, the United States has followed an aggressive universal vaccination approach, recommending annual Covid-19 booster shots for all individuals over six months old. This contrasts sharply with the more targeted strategies employed by European and other high-income countries, which primarily focus on older adults or those with underlying health risks. Despite broad authorization, fewer than 25% of Americans received boosters in the past two seasons, with uptake among children under 12 years dipping below 10% and fewer than one-third of healthcare workers participating in recent booster programs.

The FDA’s updated guidance intends to focus regulatory approvals on adults 65 and older and anyone over six months old with underlying health conditions that increase the risk of severe Covid-19. These approvals will continue to rely on immunogenicity data—measuring antibody response—to expedite access. However, for healthy individuals between the ages of 6 months and 64 years with no risk factors, the agency will now require randomized, controlled clinical trials demonstrating real-world clinical outcomes before full vaccine licensure.

This evidence-based approach aims to resolve scientific uncertainty about repeat dosing in low-risk populations, particularly those with prior infections or previous vaccinations. The FDA will encourage vaccine manufacturers to include healthy adults in postmarketing trials and, where possible, conduct placebo-controlled studies lasting at least six months. The preferred focus for these trials will be symptomatic Covid-19, with secondary outcomes including hospitalizations and mortality. The 50–64-year-old age group is viewed as a prime candidate for such studies due to global uncertainty about the value of annual boosters in this demographic.

The agency emphasized that its policy balances the need for timely vaccine access with scientific rigor. While the CDC’s definition of high-risk includes a broad spectrum of conditions—ranging from obesity to mental health disorders—the new approach ensures that vaccine availability remains wide-reaching, potentially covering 100 to 200 million Americans. At the same time, it acknowledges the lack of clear evidence for additional boosters in healthy individuals with past exposure to the virus and multiple prior vaccinations.

Covid-19 differs from influenza in key ways that support this policy shift. Unlike the flu, SARS-CoV-2 demonstrates year-round transmission, providing more opportunities to collect data outside of the typical respiratory virus season. Additionally, natural immunity appears to offer robust protection against severe outcomes. As such, the FDA believes annual updates may not be necessary unless major viral changes occur.

This revised policy underscores the FDA’s commitment to regulatory flexibility while upholding the highest scientific standards. The agency’s dual-track approach aims to maintain protection for the most vulnerable while generating critical data to guide future decisions for the broader public.

Article by multiple RFHC contributors, based upon information from the U.S. Food and Drug Administration article published in the New England Journal of Medicine, May 20, 2025.

---